KITADATE AKIHIRO 北舘明宏

… Alternative Names

Kitadate Akihiro 北舘明宏

Less

Researcher Number	90791559
Other IDs
Affiliation (Current)	2025: 秋田大学, 医学部附属病院, 講師
Affiliation (based on the past Project Information) *help	2024 – 2025: 秋田大学, 医学部附属病院, 講師 2022: 秋田大学, 医学部附属病院, 講師 2020 – 2021: 秋田大学, 医学部附属病院, 助教 2019: 秋田大学, 医学部附属病院, 医員 2017 – 2018: 亀田医療大学, 総合研究所, 客員研究員
Review Section/Research Field	Principal Investigator Basic Section 54010:Hematology and medical oncology-related / Hematology Except Principal Investigator Basic Section 49020:Human pathology-related
Keywords	Principal Investigator HDAC阻害剤 / T細胞リンパ腫 / 悪性リンパ腫 / CD38 / ハイリスク染色体異常 / 抗CD38抗体 / 多発性骨髄腫 / 薬剤耐性 / Stat3 / プロテアソーム阻害剤 … More / プロテアソーム阻害 / gp130 / JAK/STAT / ケモカインレセプター / Ｔ細胞リンパ腫 / microRNA / ボリノスタット / CCR4 / HDAC … More Except Principal Investigator 難治性リンパ腫 Less

新規免疫チェックポイント分子PSGL1を標的とした革新的リンパ腫治療開発
- Principal Investigator
  
  高田尚良
- Project Period (FY)
  2025 – 2027
- Research Category
  
  Grant-in-Aid for Scientific Research (B)
- Review Section
  
  Basic Section 49020:Human pathology-related
- Research Institution
  University of Toyama
ハイリスク多発性骨髄腫における抗CD38抗体への治療抵抗性機序解明Principal Investigator
- Principal Investigator
  
  北舘明宏
- Project Period (FY)
  2024 – 2026
- Research Category
  
  Grant-in-Aid for Scientific Research (C)
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  Akita University
Elucidation of HDAC inhibitor resistance mechanism in T-cell lymphoma and establishment of therapeutic strategies to overcome resistancePrincipal Investigator
- Principal Investigator
  
  Akihiro Kitadate
- Project Period (FY)
  2020 – 2022
- Research Category
  
  Grant-in-Aid for Early-Career Scientists
- Review Section
  
  Basic Section 54010:Hematology and medical oncology-related
- Research Institution
  Akita University
A comprehensive search for miRNAs regulated by histone deacetylase in malignant lymphomaPrincipal Investigator
- Principal Investigator
  
  Kitadate Akihiro
- Project Period (FY)
  2017 – 2019
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Hematology
- Research Institution
  Akita University
  Kameda College of Health Sciences

All 2022 2019 2018 2017

All Journal Article Presentation

[Journal Article] High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma2022
- Author(s)
  Wataru Kuroki, Akihiro Kitadate, Koichi Ishiyama, Yoshihiro Kameoka, Naoto Takahashi
- Journal Title
  
  International Journal of Hematology
  
  Volume: 116 Issue: 5 Pages: 712-722
- DOI
  10.1007/s12185-022-03418-5
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-20K17393
[Journal Article] Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients2019
- Author(s)
  Kitadate Akihiro、Kobayashi Hiroki、Abe Yoshiaki、Narita Kentaro、Miura Daisuke、Takeuchi Masami、Matsue Kosei
- Journal Title
  
  Haematologica
  
  Volume: 105 Issue: 1 Pages: e37-e40
- DOI
  10.3324/haematol.2019.219683
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K16178
[Journal Article] Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B‐cell lymphoma: a clinicopathological study of 25 patients2019
- Author(s)
  Enzan N.、Kitadate A.、Tanaka A.、Matsue K.
- Journal Title
  
  British Journal of Dermatology
  
  Volume: 181 Issue: 1 Pages: 200-201
- DOI
  10.1111/bjd.17603
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-17K16178
[Journal Article] Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.2018
- Author(s)
  Kitadate A, Ikeda S, Abe F, Takahashi N, Shimizu N, Matsue K, Tagawa H.
- Journal Title
  
  Haematologica
  
  Volume: 103(1) Issue: 1 Pages: 126-135
- DOI
  10.3324/haematol.2017.177279
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K09914, KAKENHI-PROJECT-17K16178
[Presentation] STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma2022
- Author(s)
  Yuto Takahashi, Akihiro Kitadate, Sho Ikeda, Sayaka Iwama, Ko Abe, Hiroyuki Tagawa, Hideki Wakui, Naoto Takahashi
- Organizer
  第64回米国血液学会
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K17393
[Presentation] gp130/STAT3経路はヒストン脱アセチル化酵素阻害剤抵抗性の皮膚T細胞リンパ腫の潜在的な治療標的である2022
- Author(s)
  髙橋　裕斗、北舘　明宏、池田　翔、松田　悠佳、田川　博之、髙橋　直人
- Organizer
  第81回日本癌学会学術総会
- Data Source
  KAKENHI-PROJECT-20K17393
[Presentation] gp130/STAT3経路はヒストン脱アセチル化酵素阻害剤抵抗性の皮膚T細胞リンパ腫における有望な治療標的である2022
- Author(s)
  髙橋　裕斗、北舘　明宏、池田　翔、岩間　彩夏、阿部　滉、松田　悠佳、田川　博之、涌井　秀樹、髙橋　直人
- Organizer
  第84回日本血液学会学術集会
- Data Source
  KAKENHI-PROJECT-20K17393
[Presentation] GP130/STAT3 AXIS IS A POTENTIAL THERAPEUTIC TARGET FOR HISTONE DEACETYLASE INHIBITORRESISTANT CUTANEOUS T-CELL LYMPHOMA2022
- Author(s)
  Yuto Takahashi, Akihiro Kitadate, Sho Ikeda, Sayaka Iwama, Ko Abe, Yuka Matsuda, Hiroyuki Tagawa, Hideki Wakui, Naoto Takahashi
- Organizer
  第27回欧州血液学会
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-20K17393
[Presentation] Baseline total lesion glycolysis combined with interim PET/CT is a robust predictor of outcome in patients with peripheral T-cell lymphoma2019
- Author(s)
  Akihiro Kitadate, Kentaro Narita, Kota Fukumoto, Toshiki Terao, Takafumi Tsushima, Hiroki Kobayashi, Yoshiaki Abe, Daisuke Miura, Masami Takeuchi, Youichi Machida, Naoto Takahashi, Kosei Matsue
- Organizer
  61th ASH Annual Meeting and Exposition
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K16178
[Presentation] Prognostic value of interim and end-of-treatment PET-CT in patients with mature T-cell and NK-cell lymphomas: A 10-Year Single Institution Study2018
- Author(s)
  Akihiro Kitadate
- Organizer
  60th ASH Annual Meeting and Exposition
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K16178
[Presentation] Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive malignant lymphomas2017
- Author(s)
  Akihiro Kitadate, Sho Ikeda, Fumito Abe, Naoto Takahashi, Norio Shimizu, Kosei Matsue and Hiroyuki Tagawa
- Organizer
  59th ASH Annual Meeting and Exposition
- Invited
- Data Source
  KAKENHI-PROJECT-17K16178

1. 高田尚良 (90580259)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
2. 飯岡英和 (20425416)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
3. 遠西大輔 (20825096)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
4. 高橋直人 (80344753)

# of Collaborated Projects: 1 results

# of Collaborated Products: 0 results
5. TAGWAWA Hiroyuki

# of Collaborated Projects: 0 results

# of Collaborated Products: 1 results

KITADATE AKIHIRO 北舘 明宏

Kitadate Akihiro 北舘 明宏

Research Projects

Research Products

Co-Researchers

新規免疫チェックポイント分子PSGL1を標的とした革新的リンパ腫治療開発

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

ハイリスク多発性骨髄腫における抗CD38抗体への治療抵抗性機序解明Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

Elucidation of HDAC inhibitor resistance mechanism in T-cell lymphoma and establishment of therapeutic strategies to overcome resistancePrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Review Section

Research Institution

A comprehensive search for miRNAs regulated by histone deacetylase in malignant lymphomaPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] High baseline total lesion glycolysis predicts early progression of disease within 24 months in patients with high-tumor-burden follicular lymphoma2022

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Incisional random skin biopsy, not punch biopsy, is an appropriate method for diagnosis of intravascular large B‐cell lymphoma: a clinicopathological study of 25 patients2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive mature T-cell lymphomas.2018

Author(s)

Journal Title

DOI

Data Source

[Presentation] STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma2022

Author(s)

Organizer

Data Source

[Presentation] gp130/STAT3経路はヒストン脱アセチル化酵素阻害剤抵抗性の皮膚T細胞リンパ腫の潜在的な治療標的である2022

Author(s)

Organizer

Data Source

[Presentation] gp130/STAT3経路はヒストン脱アセチル化酵素阻害剤抵抗性の皮膚T細胞リンパ腫における有望な治療標的である2022

Author(s)

Organizer

Data Source

[Presentation] GP130/STAT3 AXIS IS A POTENTIAL THERAPEUTIC TARGET FOR HISTONE DEACETYLASE INHIBITORRESISTANT CUTANEOUS T-CELL LYMPHOMA2022

Author(s)

Organizer

Data Source

[Presentation] Baseline total lesion glycolysis combined with interim PET/CT is a robust predictor of outcome in patients with peripheral T-cell lymphoma2019

Author(s)

Organizer

Data Source

[Presentation] Prognostic value of interim and end-of-treatment PET-CT in patients with mature T-cell and NK-cell lymphomas: A 10-Year Single Institution Study2018

Author(s)

Organizer

Data Source

[Presentation] Histone deacetylase inhibitors downregulate CCR4 expression and decrease mogamulizumab efficacy in CCR4-positive malignant lymphomas2017

Author(s)

Organizer

Data Source

KITADATE AKIHIRO 北舘明宏

Kitadate Akihiro 北舘明宏